This protective effect of HDACi may be through BDNF; therefore, activation of this downstream signalling molecule, for example by AMPA receptors, could be a therapeutic target or intervention applied under CCH conditions. This evidence concerns the gene BDNF and columnar cell hyperplasia of the breast.